UBS Group
VRTX icon

UBS Group’s Vertex Pharmaceuticals VRTX Stock Holding History

UBS Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26M Sell
52,400
-14,600
-22% -$6.47M ﹤0.01% 2415
2026
Q1 		$29.9M Buy
67,000
+17,300
+35% +$8.07M ﹤0.01% 2177
2025
Q4 		$22.5M Sell
49,700
-5,600
-10% -$2.41M ﹤0.01% 2476
2025
Q3 		$21.7M Buy
55,300
+9,400
+20% +$3.93M ﹤0.01% 2475
2025
Q2 		$20.4M Sell
45,900
-22,600
-33% -$10.4M ﹤0.01% 2336
2025
Q1 		$33.2M Sell
68,500
-15,300
-18% -$7.13M 0.01% 1863
2024
Q4 		$33.7M Buy
83,800
+15,700
+23% +$7.28M 0.01% 1812
2024
Q3 		$31.7M Buy
68,100
+1,800
+3% +$865K 0.01% 1480
2024
Q2 		$31.1M Sell
66,300
-14,600
-18% -$6.34M 0.01% 1351
2024
Q1 		$33.8M Sell
80,900
-4,400
-5% -$1.86M 0.01% 1307
2023
Q4 		$34.7M Buy
85,300
+8,400
+11% +$3.1M 0.01% 1207
2023
Q3 		$26.7M Buy
76,900
+19,200
+33% +$6.71M 0.01% 1270
2023
Q2 		$20.3M Buy
57,700
+16,900
+41% +$5.69M 0.01% 1439
2023
Q1 		$12.9M Buy
+40,800
New +$12.2M ﹤0.01% 1709
2022
Q2 		– Sell
-20,000
Closed -$5.22M – 11000
2022
Q1 		$5.22M Sell
20,000
-39,600
-66% -$9.4M ﹤0.01% 2500
2021
Q4 		$13.1M Sell
59,600
-23,122
-28% -$4.5M ﹤0.01% 1912
2021
Q3 		$15M Hold
82,722
– – ﹤0.01% 1720
2021
Q2 		$16.7M Buy
82,722
+22,300
+37% +$4.66M 0.01% 1632
2021
Q1 		$13M Buy
+60,422
New +$13.3M ﹤0.01% 1746
2018
Q4 		– Sell
-5,000
Closed -$964K – 8326
2018
Q3 		$964K Buy
+5,000
New +$890K ﹤0.01% 3882
2017
Q2 		– Sell
-9,500
Closed -$1.04M – 8011
2017
Q1 		$1.04M Buy
+9,500
New +$836K ﹤0.01% 3497
2016
Q1 		– Sell
-600
Closed -$76K – 8225
2015
Q4 		$76K Hold
600
– – ﹤0.01% 5442
2015
Q3 		$62K Hold
600
– – ﹤0.01% 5634
2015
Q2 		$74K Sell
600
-500
-45% -$63K ﹤0.01% 5652
2015
Q1 		$130K Sell
1,100
-600
-35% -$71.9K ﹤0.01% 5215
2014
Q4 		$202K Buy
+1,700
New +$191K ﹤0.01% 5038

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

UBS Group's VRTX Position: Q2 2026 in Review

UBS Group increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q2 2026, buying an estimated $36.2M and bringing the position to 712,259 shares worth $354M. The position accounts for 0.05% of the portfolio, ranked #414.

UBS Group first reported a position in VRTX in Q4 2014 and has held it in 47 quarters since. The position peaked at $360M in Q3 2024. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • UBS Group held 712,259 shares of Vertex Pharmaceuticals worth $354M as of Q2 2026.
  • UBS Group bought 81,641 Vertex Pharmaceuticals shares in Q2 2026, an estimated $36.2M.
  • Vertex Pharmaceuticals made up 0.05% of UBS Group's portfolio in Q2 2026, its #414 holding.
  • UBS Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Vertex Pharmaceuticals position peaked at $360M in Q3 2024.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.